Bayer Aktiengesellschaft (VIE:BAYN)
Austria · Delayed Price · Currency is EUR | Market Cap | 47.23B +78.4% |
| Revenue (ttm) | 45.38B -1.7% |
| Net Income | -1.74B |
| EPS | -1.77 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.27 |
| Dividend | 0.11 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 3,384 |
| Open | 48.65 |
| Previous Close | 48.60 |
| Day's Range | 47.79 - 48.74 |
| 52-Week Range | 25.87 - 53.76 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial StatementsNews
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.
EQS-PVR: Bayer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribu...
Robigo announces Series A funding led by Leaps by Bayer
Robigo announced a Series A funding led by Leaps by Bayer (BAYRY) with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The round will accelerate the commercial lau...
Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Robigo, a biotechnology company engineering no-compromise biological solutions for crop protection, today announced a Series A funding led by Leaps by Bayer with par...
Bayer receives FDA approval for Kerendia for CKD with type 1 diabetes
Bayer (BAYRY) announced that theFDA approved Kerendia to reduce urinary albumin-to-creatinine ratio, which is expected to reduce the risk of sustained estimated glomerular filtration rate decline and ...
Bayer's Kerendia Wins FDA Approval As First New CKD Treatment For Type 1 Diabetes In 30 Years
(RTTNews) - Bayer AG (BAYRY) announced that the U.S. FDA has approved Kerendia as the first new treatment in more than three decades for adults with chronic kidney disease (CKD) associated with type 1...
Bayer: FDA Approves Kerendia To Treat Chronic Kidney Disease Associated With Type 1 Diabetes
(RTTNews) - Bayer (BYR.L, BAY.MI, BAYN.DE) announced the FDA has approved Kerendia or finerenone for the treatment of adult patients with chronic kidney disease associated with type 1 diabetes. The ap...
Bayer's KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA® (finerenone) to reduce urinary albumin-to-creatinine ratio (UAC...
Bayer’s KERENDIA (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes
Bayer Summary Bayer today announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce th...
Bayer's Monsanto unit urges Missouri judge to approve $7.25 billion Roundup settlement
Bayer's Monsanto unit urged a Missouri judge on Monday to approve its $7.25 billion proposed settlement of lawsuits alleging that its weedkiller Roundup causes cancer, saying there is no other way to...
Bayer faces pivotal test of US$7.25 billion Roundup settlement in Missouri court
Bayer’s Monsanto unit seeks approval of a US$7.25 billion settlement to resolve lawsuits alleging that its popular weedkiller Roundup causes cancer.
Bayer faces pivotal test of $7.25 billion Roundup settlement in Missouri court
Bayer's Monsanto unit heads to a Missouri state court on Monday seeking approval of a $7.25 billion settlement that could resolve tens of thousands of U.S. lawsuits alleging that its popular weedkill...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
WHIPPANY, N.J.--(BUSINESS WIRE)--Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile...
Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road
Amid growing concerns over misinformation around health and science, Bayer launched a nationwide tour of its Science Delivers mobile interactive experience. The mobile display hits the road at a criti...
Bayer price target raised to EUR 65 from EUR 60 at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on Bayer (BAYRY) to EUR 65 from EUR 60 and keeps a Buy rating on the shares. The firm adjusted targets…
Bayer granted accelerated approval for Hyrnuo by FDA
Bayer (BAYRY) announced that following Priority Review and Breakthrough Therapy Designation, the FDA has granted accelerated approval for Hyrnuo, for the first-line treatment of adult patients with lo...
U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J.--(BUSINESS WIRE)--U.S. FDA Grants Accelerated Approval to Bayer's HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated NSCLC.
U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer
Bayer announced today that following Priority Review and Breakthrough Therapy Designation, the U.S. Food and Drug Administration (FDA) has granted accelerated approval for HYRNUO (sevabertinib), for t...
FDA grants accelerated approval to added indication for Bayer’s sevabertinib
The Food and Drug Administration granted accelerated approval to sevabertinib from Bayer (BAYRY) Healthcare Pharmaceuticals, a kinase inhibitor, for adult patients with locally advanced or metastatic ...
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold Winter Canola for Biofuels Production
Commitment aims to support the growth of winter canola in the Southern Great Plains of the U.S., as a feedstock for renewable diesel and sustainable aviation fuel Bayer and Neste, the world's lead...
Bayer and Neste Close Commercial Agreement to Jointly Scale newgold® Winter Canola for Biofuels Production
MONHEIM, Germany & ST. LOUIS--(BUSINESS WIRE)--Bayer and Neste, the world's leading producer of renewable diesel and sustainable aviation fuel, have finalized a commercial agreement to jointly scale B...
Bayer initiates Phase II study of BAY 3670549 in patients with AFib
Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 inhibit...
BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial (NCT07625215) evaluating BAY 3670549, an investigational highly selective G-protein-coupled in...
BAYER AG: AskBio's Viralgen,EpilepsyGTx Partner To Advance AAV Gene Therapy For Epilepsy
(RTTNews) - EpilepsyGTx, a biotechnology company focused on gene therapies for drug-resistant epilepsy, has entered into a collaboration with Viralgen, a leading AAV contract development and manufactu...
Bayer Crop Science Targets €3B Cash Flow by 2029 With Seeds-Led Growth
Bayer Aktiengesellschaft ETR: BAYN outlined progress on its Crop Science division's five-year framework at a 2026 innovation event in Iowa, reaffirming targets for above-market sales growth, a mid-20s...